The inclusion criteria were patients with limited extrahepatic disease, 800 mL or greater of uninvolved liver, and no cirrhosis or Child-Pugh A. The researchers evaluated the association of common genetic alterations like BRAF, EGFR, HER2, KRAS, NRAS, PIK3CA, and TP53 and tumour characteristics with control rates. The gene discussed is KRAS; the disease is neoplasm.